Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

263.00 -1.21 (-0.46%)
Streaming Delayed Price Updated: 1:44 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
49 50 Next >
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Top 5 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected
The company expects Humira sales to fall 37% this year. 
Via Investor's Business Daily
AbbVie Profit Outlook Widely Misses As The U.S. Humira Battle Kicks Off
The company's fourth quarter also came in mixed with lighter-than-expected sales. 
Via Investor's Business Daily
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
Why Amgen Stock Wilted on Wednesday
The company's latest quarter wasn't its most impressive. 
Via The Motley Fool
Amgen Sinks On Mixed Earnings As 2023 Guidance Comes Up Short
Amgen reported lighter-than-expected earnings, but sales beat forecasts. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Via Benzinga
Beat the Dow Jones With This Unstoppable Dividend Stock
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years. 
Via The Motley Fool
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?
Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Earnings Preview: Amgen
Via Benzinga
Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
The 7 Most Undervalued Dow Stocks to Buy in February 2023
If you’re looking for the best deals among the most iconic enterprises, these are the most undervalued Dow stocks to buy. 
Via InvestorPlace
Why Amgen Shares Are Falling
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 3.85% to $242.69 Wednesday morning after the company reported fourth-quarter financial results and issued FY23 revenue guidance below estimates.... 
Via Benzinga
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
Via Benzinga
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Amgen launched its biosimilar knockoff on Tuesday at a steep discount. 
Via Investor's Business Daily
2 Top Passive-Income Stocks to Own in 2023
These dividend stocks can deliver both downside protection and capital appreciation. 
Via The Motley Fool
Nasdaq, S&P Futures Lower As Powell & Team Kick Off 2-Day Fed Meeting: Analyst Says Positive January Harbinger Of Good Times
Trading in the major U.S. index futures suggests stocks may extend their losses for a second straight session. 
Via Benzinga
Earnings Scheduled For January 31, 2023
Companies Reporting Before The Bell • Biophytis (NASDAQ:BPTS) is projected to report earnings for its first quarter. 
Via Benzinga
Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts
Wall street is buzzing over Amgen layoffs today. The biotech company announced it laid off 300 of its U.S. employees. 
Via InvestorPlace
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
Developing new products will be key to the success of both of these biotech leaders. 
Via The Motley Fool
Dogs of the Dow 2023: 5 Dividend Stocks for Income Investors
The 2023 Dogs of the Dow feature several stocks investors should consider for their income portfolios. Here are the top five picks. 
Via InvestorPlace
6 Dividend Growth Stocks
Interested in knowing about companies that are paying their shareholders even bigger dividends than before? Today I want to tell you about six dividend growth stocks that just increased their... 
Via Talk Markets
3 Dividend Stocks You Can Safely Hold for Years
Look for the top companies in businesses the world perpetually needs. 
Via The Motley Fool
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.  
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.